Antineoplastic strategy: Irreversible tumor blood flow stasis induced by the combretastatin A-4 derivative AVE8062 (AC7700)

Chemotherapy

Volumn 51, Issue 6, 2005, Pages 357-360

  Hori, Katsuyoshi ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

AVE8062; Combretastatin A 4; Tumor blood flow

Indexed keywords

ANTINEOPLASTIC AGENT; COMBRETASTATIN A4; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; VASCULAR TARGETING AGENT;

ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; HUMAN; NONHUMAN; PRIORITY JOURNAL; SIDE EFFECT; SOLID TUMOR; TISSUE BLOOD FLOW; TUMOR BLOOD FLOW; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; MICROCIRCULATION; NEOPLASMS; RATS; REGIONAL BLOOD FLOW; SERINE; STILBENES;

EID: 27544511815     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000088961     Document Type: Article

References (10)

1. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garcia-Kendall D: Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 1989;45:209-211.
2. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ: Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997;57:1829-1834.
3. Ohsumi K, Nakagawa R, Fukuda Y, Hatanaka T, Morinaga Y, Nihei Y, Ohishi K, Suga Y, Akiyama Y, Tsuji T: Novel combretastatin analogues effective against murine solid tumors: design and structure-activity relationships. J Med Chem 1998;41:3022-3032.
4. Hori K, Saito S, Nihei Y, Suzuki M, Sato Y: Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700. Jpn J Cancer Res 1999;90:1026-1038.
5. Nihei Y, Suga Y, Morinaga Y, Ohishi K, Okano A, Ohsumi K, Hatanaka T, Nakagawa R, Tsuji T, Akiyama Y, Saito S, Hori K, Sato Y, Tsuruo T: A novel combretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors. Jpn J Cancer Res 1999;90:1016-1025.
6. Nihei Y, Suzuki M, Okano A, Tsuji T, Akiyama Y, Tsuruo T, Saito S, Hori K, Sato Y: Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy. Jpn J Cancer Res 1999;90:1387-1395.
7. Hori K, Saito S, Sato Y, Kubota K: Stoppage of blood flow in 3-methylcholanthrene-induced autochthonous primary tumor due to a novel combretastatin A-4 derivative, AC7700, and its antitumor effect. Med Sci Monit 2001;7:26-33.
8. Hori K, Saito S, Kubota K: A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs. Br J Cancer 2002;86:1604-1614.
9. Hori K, Saito S: Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis. Br J Cancer 2003;89:1334-1344.
10. Sörgel F: The return of Ehrlich's 'therapia magna sterilisans' and other Ehrlich concepts? Series of papers honoring Paul Ehrlich on the occasion of his 150th birthday. Chemotherapy 2004;50:6-10.